TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Balance Training in Patients With Rotator Cuff Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Verification of the diagnosis of rotator cuff disease by a medical practitioner via radiological techniques.~* Pain due to unilateral rotator cuff disease at least four weeks.~Exclusion Criteria:~* Systemic pathology including inflammatory joint disease.~* More than %50 restriction of passive range of motion in two or more planes.~* History of major surgery on the lower extremities and shoulder regions.~* Acute or chronic pain in the spine or lower extremities.~* An injury of the lower extremities during the last six months which affected functional capabilities.~* Any kind of neurological complaint.~* Cardiovascular diseases which affect balance.~* Acute dizziness~* Medications which affected balance~* Subjects who performed balance training

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rehabilitation and balance training (Type: EXPERIMENTAL): Each patient will attend rehabilitation program for three days per week for six weeks. Patients will receive balance training in addition to supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program. Balance training will be non-supervised program.
- Rehabilitation program (Type: ACTIVE_COMPARATOR): Each patient will attend rehabilitation program for three days per week for six weeks.~Patients will receive supervised rehabilitation program which is including patient education, stretching and strengthening exercises.~Patients will also implement home exercise program.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Addressing Psychosocial Needs and HIV Risk in Indian MSM

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Man who has had unprotected sex with another man in past 3 months~* Resident of Tamil Nadu state, India~* Identifies as Khothi or Double-decker~Exclusion Criteria:~* Does not identify as a man (i.e. Hijra/ Ali/Transgendered)~* Under age 18~* Unable to complete or understand informed consent procedures

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HIV/STI voluntary counseling and testing (Type: NO_INTERVENTION): Participants enrolled in the control arm will receive study assessments only.
- Behavioral intervention (Type: EXPERIMENTAL): Participants enrolled in the experimental condition will receive 4 group sessions and 4 individual sessions over 3 months. This intervention focuses on psychosocial concerns and HIV risk for MSM in India.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Post Hematopoietic Stem Cell Transplantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria~* Patients who had hematopoietic stem cell transplantation (HSCT) for beta-thalassemia major~* hematopoietic stem cell transplantation (HSCT) was performed minimum 6 months and maximum 2 years ago~* The washout period after the immunosuppressive therapy should be at least 3 months.~* Signifacant IOL should be present including:~A. Serum ferritin \>1000 μg/L or B. cardiac MRI \<20 ms or C. liver iron concentration ≥ 5 mg/g dry weight measured by R2\* MRI~Exclusion Criteria~* Patients who had any contraindication for treatment with deferasirox according to the prescribing information~  •Patients who depended on transfusion~* Patients with clinical symptoms of cardiac dysfunction (shortness of breath at rest or exertion, orthopnea, exercise intolerance, lower extremity edema, arrhythmias)~* Patients who were experiencing severe complication of HSCT e.g. acute Graft-versus host disease (GVHD)~* Significant proteinuria / Increase in serum creatinine

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ICL670 (Type: EXPERIMENTAL): Oral dose of ICL670 at 10 mg/kg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tofacitnib for the Treatment of Alopecia Areata and Variants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>= 18 years old~* Diagnosis of alopecia areata with \>50% scalp involvement, alopecia totalis, or alopecia universalis~* Hair loss present for at least 6 months~* No treatment for alopecia areata in past 2 months~* No evidence of hair regrowth~* Females of childbearing potential must use birth control while taking the medication and there must be a negative pregnancy test documented prior to starting the medication~Exclusion Criteria:~* Age \<18 years old~* Patients have received treatment known to affect alopecia areata within 2 months of enrolling in the study~* Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)~* Patients known to be HIV or hepatitis B or C positive~* Patients with positive tuberculin skin test or positive QuantiFERON TB test~* Patients with leukopenia or anemia~* Patients with renal or hepatic impairment~* Patients with peptic ulcer disease~* Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNH-alpha inhibitors~* Women of childbearing potential who are unable or unwilling to use birth control while taking the medication~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Tofacitinib Administration (Type: EXPERIMENTAL): 5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Continuous Combined Hormone Replacement Therapy and Clodronate on Bone Mineral Density (BMD) in Osteoporotic Women

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal~* BMD T-score \<-2.5sd~Exclusion Criteria:~* None

- Gender: FEMALE
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Clodronate 800 mg / day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
- 2 (Type: PLACEBO_COMPARATOR): Placebo 2 tablets/ day + estradiol 2 mg + norethisterone acetate 1 mg / day for five years.
- 3 (Type: ACTIVE_COMPARATOR): Clodronate 800 mg / day for five years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Fibrocaps™ in Surgical Bleeding

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Has signed an institutional review board/independent ethics committee (IRB/IEC)-approved informed consent document~2. Is undergoing one of the 4 surgical procedures described~3. Is at least 18 years old at time of consent~4. If female and of child-bearing potential, has negative pregnancy test during screening and is not breast-feeding~5. If able to reproduce, agrees to use a medically accepted form of contraception from the time of consent to completion of all follow-up study visits when engaging in heterosexual intercourse~6. Has not received blood transfusion between screening and study treatment~7. Has mild to moderate surgical bleeding~8. Does not have intra-operative complications~9. Has not used a topical hemostat containing thrombin prior to study treatment~10. Has an approximate bleeding site surface area of less than or equal to 100 cm\^2~Exclusion Criteria:~1. Has known antibodies or hypersensitivity to thrombin or other coagulation factors~2. Has history of heparin-induced thrombocytopenia (only for vascular subjects where heparin use is required)~3. Has known allergy to gelatin sponge~4. Is unwilling to receive blood products~5. Has liver enzymes appropriate for the study, considering their disease~6. Has appropriate level of platelets per liter (PLT/L) during screening~7. Has any clinically-significant coagulation disorder that may interfere with the assessment of efficacy or pose a safety risk to the subject according to the Investigator, or baseline abnormalities during screening that are not explained by current drug treatment (e.g., warfarin, heparin)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fibrocaps + Gelatin Sponge (Type: EXPERIMENTAL): Single application of Fibrocaps plus gelatin sponge.
- Gelatin Sponge (Type: ACTIVE_COMPARATOR): Single application of gelatin sponge alone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Microbiome and Metagenome in Percutaneous Osseointegrated Prostheses (MMPOP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Is a US military Veteran with transfemoral limb loss, that occurred at least 6 months prior to consent, and that the amputation is not a result of dysvascular disease.~2. Is at least 18 years of age or older.~3. Has previously used or is currently using a socket suspension technology prosthesis~4. Has, in the opinion of the investigator, normal cognitive function and no physical limitations, addictive diseases, or underlying medical conditions including tobacco use (continued testing for tobacco use will be performed at screening) that may prevent the subject from being an appropriate study candidate.~5. Is willing, able, and committed to participation in baseline and follow-up evaluations for the entire duration of the study.~6. Can provide written informed consent to participate.~Exclusion Criteria:~1. Is currently on active or reserve military duty~2. Has experienced systemic bacterial infection or localized infection at the stump site within the previous 6 months~3. Has had more than 1 limb amputated~4. Has a body mass index (BMI) 30~5. Has insulin dependent diabetes mellitus (IDDM) or has adult onset DM with a glycated hemoglobin (HbA1c) \> 53 mmol/mol (7.0%) at screening~6. Has residual femur bone length of less than 25% of the length of the contralateral femur.~7. Has clinically diagnosed vascular compromise proximal to the surgical site~8. Is pregnant at the time of surgery or plans to become pregnant within the first year of follow-up~9. Has evidence of recent tobacco use (urine cotinine test \> 300 ng/mL \[1703 nmol/L\]) and is not committed to a smoking-cessation program~10. Has renal insufficiency (defined as serum creatinine of 1.8 mg/dL) or is currently receiving renal dialysis~11. Is currently involved in or plans to be involved in high levels of physical activity (competitive sports, heavy physical labor, etc) during the first 12 months of the rehabilitation stage~12. Has muscular, neurologic or vascular deficiencies that may compromise the bone or soft tissue healing of the affected extremity~13. Has anemia characterized by a hemoglobin of 11 g/dL at the time of surgery~14. Is currently on oral anticoagulation (excluding low-dose aspirin for cardiac prophylaxis)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- POP 10 patient cohort (Type: None): This is an observational study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed primary cutaneous or unknown primary melanoma, including 1 of the following stages:~  * Stage IIIB or IIIC disease~    * Unresected, in-transit lymph node metastases (N2c or N3)~ * Stage IV disease~    * Distant skin, subcutaneous, lymph node, or pulmonary metastases (M1a or M1b)~      * No cerebral, bone, or other visceral metastases~* At least 1 measurable or evaluable lesion~  * Small-volume multiple cutaneous deposits allowed~* Progressive disease, as defined by 1 of the following criteria:~  * At least 20% increase in size in ≥ 1 measurable or evaluable lesion~ * Appearance of ≥ 1 new lesion since or during last treatment (if applicable) AND within the past 3 months~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-1~Life expectancy~* At least 6 months~Hematopoietic~* WBC ≥ 3,000/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10.0 g/dL (transfusion allowed)~Hepatic~* SGOT and SGPT ≤ 2.5 times upper limit of normal (ULN)~* Lactic dehydrogenase normal~* No active hepatitis B or C infection~Renal~* Creatinine ≤ 1.5 times ULN~Immunologic~* No history of autoimmune disease~  * Vitiligo allowed~* No history of immunodeficiency syndrome~* No active bacterial, viral, or fungal infection within the past 72 hours~* HIV-1 or -2 negative~* Human T-cell lymphotrophic virus-I or -II negative~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* No contraindication to apheresis~* No other significant medical or surgical condition that would preclude study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior vaccine therapy with ≥ 1 melanoma antigen or peptide~* More than 4 weeks since prior biologic therapy~Chemotherapy~* More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)~Endocrine therapy~* No concurrent chronic systemic corticosteroids~Radiotherapy~* More than 4 weeks since prior radiotherapy~Surgery~* Not specified~Other~* More than 4 weeks since prior investigational products~* More than 4 weeks since prior chronic systemic immunosuppressive treatment~* No concurrent medication or treatment regimen that would prelude study participation~* No other concurrent anticancer treatment~* No other concurrent immunosuppressive treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Different Doses of Dexmedetomidine on Propofol Requirement for Loss of Consciousness Undergoing Bispectral Index: a Double-blinded, Placebo-controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* ASA physical status I-II~* Aged 18-65 years~* Body Mass Index 18.0～24.5 kg/m2~* Without hearing impairment~Exclusion Criteria:~* Bradycardia~* Atrioventricular block~* Neurologic disorder and recent use of psychoactive medication~* Allergic to the drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group control (Type: PLACEBO_COMPARATOR): 24 eligible patients are received equal volumes of saline intravenously for 10 minutes
- Group dexmedetomidine 0.5 µg/kg (Type: ACTIVE_COMPARATOR): 24 eligible patients are received dexmedetomidine 0.5 µg/kg intravenously for 10 minutes
- Group dexmedetomidine 1.0 µg/kg (Type: ACTIVE_COMPARATOR): 25 eligible patients are received dexmedetomidine 1.0 µg/kg intravenously for 10 minutes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metoclopramide for Post Traumatic Headache

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Included patients will be adults who meet International Classification of Headache Disorders criteria for acute post-traumatic headache. These are as follows:~* Traumatic injury to the head has occurred~* Headache has developed within 7 days of injury to the head~* Headache is not better accounted for by another diagnosis (eg, previous history of migraine or tension-type headache)~The headache must be rated as moderate or severe in intensity at the time of initial evaluation.~Exclusion Criteria:~Patients will be excluded if more than ten days have elapsed since the head trauma, if the headache has already been treated with an anti-dopaminergic medication, or for medication contra-indications including pheochromocytoma, seizure disorder, Parkinson's disease, use of MAO inhibitors, and use of anti-rejection transplant medications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metoclopramide (Type: EXPERIMENTAL): Metoclopramide 20mg + diphenhydramine 25mg + 100cc normal saline, administered as an intravenous drip
- Placebo (Type: PLACEBO_COMPARATOR): Normal saline, administered as an intravenous drip

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are 50 years of age or older on the day of screening~* Have an understanding of the study, agree to its provisions, have the ability to adhere to the provisions of the study and give written informed consent prior to study entry~* If female and capable of bearing children,have a negative urine pregnancy test result within 24 hours prior to the vaccination on Study Day 0 and agree to employ adequate birth control measures.~Exclusion Criteria:~* History of severe allergic reaction or anaphylaxis to egg protein or any other component of the Vero cell-derived influenza vaccine or the egg-derived influenza vaccine~* Oral temperature of \>= 99.5°F (37.5°C) on the day of vaccination in this study (Note: Subjects meeting this exclusion criterion may be rescheduled for vaccination and study entry at a later date if certain requirements \[in the study protocol\] are met)~* Rash or dermatologic condition or tattoos which may interfere with injection site reaction rating~* Blood transfusion or immunoglobulins received within 90 days of study entry~* Live vaccine received within 4 weeks or inactivated vaccine or subunit vaccine received within 2 weeks of study entry~* Previous vaccination against influenza for the 2008/2009 northern hemisphere influenza season~* Functional or surgical asplenia (e.g. from a history of hemoglobinopathies, leukemias, or lymphomas)~* Diagnosed immunodeficiency as a result of a pathological condition~* Pharmacologically induced immunodeficiency as a result of prescribed administration of corticosteroids (e.g., any systemic administration of corticosteroids or an inhaled dose equivalent to 800 mg of beclomethasone dipropionate) or chemotherapeutics or as a result of radiation therapy or any other modality capable of altering normal immunologic response~* Known or suspected problem with drug or alcohol abuse~* Investigational drug received within 6 weeks prior to study entry or concurrent participating in a clinical study that includes the administration of an investigational product~* Subjects who are a member of the team conducting this study or are in a dependent relationship with the study investigator. Dependent relationships include close relatives (i.e., children, spouse/partner, siblings, parents) as well as employees of the investigator.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Vero cell-derived, trivalent, seasonal influenza vaccine
- 2 (Type: ACTIVE_COMPARATOR): Licensed egg-derived, trivalent seasonal influenza vaccine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Differential Regulation of VEGF, Cadherin, Angiopietin 2 by Trigger Oocyte Maturation With GnRHa vs hCG in Donors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Donors~Exclusion Criteria:~* Important diseases

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 34 Years
- Healthy Volunteers: t

Study Arms:
- Antagonist-hCG for triggering (Type: None): Protocol with antagonist and hCG to trigger oocyte maturation
- Antagonist-aGnRH for triggering (Type: None): Protocol with antagonist and 0,2 mg triptorelin to trigger oocyte maturation
- Long protocol-hCG for triggering (Type: None): Long Protocol and hCG to trigger oocyte maturation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete